» Articles » PMID: 36612237

MiRNAs and SnoRNAs in Bone Metastasis: Functional Roles and Clinical Potential

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2023 Jan 8
PMID 36612237
Authors
Affiliations
Soon will be listed here.
Abstract

Bone is a frequent site of metastasis. Bone metastasis is associated with a short-term prognosis in cancer patients, and current treatments aim to slow its growth, but are rarely curative. Thus, revealing molecular mechanisms that explain why metastatic cells are attracted to the bone micro-environment, and how they successfully settle in the bone marrow-taking advantage over bone resident cells-and grow into macro-metastasis, is essential to propose new therapeutic approaches. MicroRNAs and snoRNAs are two classes of small non-coding RNAs that post-transcriptionally regulate gene expression. Recently, microRNAs and snoRNAs have been pointed out as important players in bone metastasis by (i) preparing the pre-metastatic niche, directly and indirectly affecting the activities of osteoclasts and osteoblasts, (ii) promoting metastatic properties within cancer cells, and (iii) acting as mediators within cells to support cancer cell growth in bone. This review aims to highlight the importance of microRNAs and snoRNAs in metastasis, specifically in bone, and how their roles can be linked together. We then discuss how microRNAs and snoRNAs are secreted by cancer cells and be found as extracellular vesicle cargo. Finally, we provide evidence of how microRNAs and snoRNAs can be potential therapeutic targets, at least in pre-clinical settings, and how their detection in liquid biopsies can be a useful diagnostic and/or prognostic biomarker to predict the risk of relapse in cancer patients.

Citing Articles

Specific modulation of 28S_Um2402 rRNA 2'--ribose methylation as a novel epitranscriptomic marker of ZEB1-induced epithelial-mesenchymal transition in different mammary cell contexts.

Morin C, Paraqindes H, Nguyen Van Long F, Isaac C, Thomas E, Pedri D NAR Cancer. 2025; 7(1):zcaf001.

PMID: 39877292 PMC: 11773364. DOI: 10.1093/narcan/zcaf001.


Protective effects of miR-24-2-5p in early stages of breast cancer bone metastasis.

Puppo M, Croset M, Ceresa D, Valluru M, Canuas Landero V, Hernandez Guadarrama M Breast Cancer Res. 2024; 26(1):186.

PMID: 39696397 PMC: 11656574. DOI: 10.1186/s13058-024-01934-2.


MicroRNAs and RNA-Binding Protein-Based Regulation of Bone Metastasis from Hepatobiliary Cancers and Potential Therapeutic Strategies.

Fagoonee S, Weiskirchen R Cells. 2024; 13(23).

PMID: 39682684 PMC: 11640337. DOI: 10.3390/cells13231935.


Predictive and prognostic biomarkers of bone metastasis in breast cancer: current status and future directions.

Wang S, Wu W, Lin X, Zhang K, Wu Q, Luo M Cell Biosci. 2023; 13(1):224.

PMID: 38041134 PMC: 10693103. DOI: 10.1186/s13578-023-01171-8.


MiR-662 is associated with metastatic relapse in early-stage breast cancer and promotes metastasis by stimulating cancer cell stemness.

Puppo M, Valluru M, Croset M, Ceresa D, Iuliani M, Khan A Br J Cancer. 2023; 129(5):754-771.

PMID: 37443350 PMC: 10449914. DOI: 10.1038/s41416-023-02340-9.

References
1.
Dsouza V, Adiga D, Sriharikrishnaa S, Suresh P, Chatterjee A, Kabekkodu S . Small nucleolar RNA and its potential role in breast cancer - A comprehensive review. Biochim Biophys Acta Rev Cancer. 2021; 1875(1):188501. DOI: 10.1016/j.bbcan.2020.188501. View

2.
Oh-Hohenhorst S, Lange T . Role of Metastasis-Related microRNAs in Prostate Cancer Progression and Treatment. Cancers (Basel). 2021; 13(17). PMC: 8431208. DOI: 10.3390/cancers13174492. View

3.
Hong D, Kang Y, Borad M, Sachdev J, Ejadi S, Lim H . Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. Br J Cancer. 2020; 122(11):1630-1637. PMC: 7251107. DOI: 10.1038/s41416-020-0802-1. View

4.
Ma L, Teruya-Feldstein J, Weinberg R . Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 2007; 449(7163):682-8. DOI: 10.1038/nature06174. View

5.
Katagiri T, Yamaguchi A, Komaki M, Abe E, Takahashi N, Ikeda T . Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage. J Cell Biol. 1994; 127(6 Pt 1):1755-66. PMC: 2120318. DOI: 10.1083/jcb.127.6.1755. View